Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Ptc Therapeutics, Inc. (PTCT)

A forensic read on Ptc Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

3.7

Distress distance

Watch

Earnings quality

Forensic signals

-147.6

P / E (ttm)

$6.2B

Market cap

0.00%

Dividend yield

114.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Ptc Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.7, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by inventory days.

What the filings flag

532d

FY2018→FY2019

Inventory days. Days inventory outstanding moved from 387 to 532 FY2018→FY2019 (against cost of goods sold; inventory +20% vs -4% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.

+7.2%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +23% over the last 3 years to FY2025 (+7.2%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~7.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~19%.

4% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 4% of revenue and 11% of free cash flow in FY2025 — about $0.84 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 7.3% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.

Key fundamentals

Latest Revenue$1.73B

Revenue Growth YoY+114.5%

Revenue CAGR (3yr)+35.3%

Net Margin39.4%

Free Cash Flow$702.3M

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Ptc Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.